Investors look for pipeline news in upcoming Genmab report
The arbitration case against Johnson & Johnson did not go Genmab’s way, and the earnings gap must therefore be closed after 2023.
In connection with the upcoming annual report, Genmab investors’ attention is firmly focused on the company’s future plans and not least on measures to mitigate the expected revenue decline when the Darzalex patent expires in 2030, writes business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
